Major advances have been made in the understanding of the pathophysiology of psoriasis.
Objectives:
The authors review the role of interleukin (IL) 17 in the pathogenesis of psoriasis and provide updates on approved and investigational therapies targeting IL-17 and the IL-17 receptor.
Methods:
A PubMed search was performed for relevant literature.
Conclusion:
The IL-23/Th17 signaling pathway (including IL-17) plays a central role in the pathogenesis of psoriasis. Biologic agents that block IL-17 (secukinumab and ixekizumab) or its receptor (brodalumab) are effective and safe for the treatment of psoriasis.
BoehnckeWH. Etiology and pathogenesis of psoriasis. Rheum Dis Clin North Am. 2015;41(4):665-675.
5.
LyndeCWPoulinYVenderRBourcierMKhalilS. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141-150.
6.
WilsonNJBonifaceKChanJR. Development, cytokine profile and function of human interleukin 17-producing helper T-cells. Nat Immunol. 2007;8(9):950-957.
7.
MiossecPKollsJK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Disc. 2012;11:763-776.
8.
GhoreschiKLaurenceAYangXPHiraharaKO’SheaJJ. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol. 2011;32:395-401.
9.
HeZJinLLiuZF. Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis. Br J Dermatol. 2012;167(1):191-193.
10.
OuyangW. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev. 2010;21(6):435-441.
11.
EyerichSEyerichKPenninoD. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119:3573-3585.
12.
CoimbraSFigueiredoASantos-SilvaA. Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis. Core Evid. 2014;9:89-97.
13.
CoimbraSOliveiraHReisF. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumor necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163(6):1282-1290.
14.
IwakuraYNakaeSSaijoSIshigameH. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 2008;226:57-79.
15.
MatsuzakiGUmemuraM. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol. 2007;51(12):1139-1147.
16.
LowesMAKikuchiTFuentes-DuculanJ. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T-cells. J Invest Dermatol. 2008;128(5):1207-1211.
17.
PietrzakATZalewskaAChodorowskaG. Cytokines and anticytokines in psoriasis. Clin Chim Acta. 2008;394(1-2):7-21.
18.
WatanabeHKawaguchiMFujishimaS. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J Invest Dermatol. 2009;129(3):650-656.
19.
NogralesKEZabaLCGuttman-YasskyE. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092-1102.
20.
HarperEGGuoCRizzoH. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129(9):2175-2183.
21.
LiangSCTanXYLuxenbergDP. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203(10):2271-2279.
22.
ContiHRGaffenSL. IL-17-mediated immunity to the opportunistic fungal pathogenCandida albicans. J Immunol. 2015;195(3):780-788.
23.
ZabaLCFuentes-DuculanJEungdamrongNJ. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129(1):79-88.
24.
FossiezFDjossouOChomaratP. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183(6):2593-2603.
25.
CarrierYMaHLRamonHE. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131(12):2428-2437.
26.
NumasakiMFukushiJOnoM. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620-2627.
27.
NakajimaKKandaTTakaishiM. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol. 2011;186(7):4481-4489.
28.
TausendWDowningCTyringS. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg. 2014;18(3):156-169.
29.
RizzoHLKagamiSPhillipsKGKurtzSEJacquesSLBlauveltA. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186(3):1495-1502.
30.
EbiharaSDateFDongYOnoM. Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice. Autoimmunity. 2015;48(4):259-266.
31.
TakahashiHTsujiHIshida-YamamotoAIizukaH. Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet B phototherapy more than twice a week. J Dermatol. 2013;40(6):424-427.
32.
Johnson-HuangLMSuarez-FarinasMSullivan-WhalenMGilleaudeauPKruegerJGLowesMA. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol. 2010;130(11):2654-2663.
33.
ChenYQianTZhangDYanHHaoF. Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis. Immunotherapy. 2015;7(9):1023-37.
34.
SanfordMMcKeageK. Secukinumab: first global approval. Drugs. 2015;75(3):329-338.
35.
PappKALangleyRGSigurgeirssonB. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168:412-421.
36.
RichPSigurgeirssonBThaciD. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402-411.
37.
LangleyRGElewskiBELebwohlM. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.
38.
BlauveltAPrinzJCGottliebAB. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484-493.
39.
ThaçiDBlauveltAReichK. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400-409.
40.
MrowietzULeonardiCLGirolomoniG. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27-36.
41.
PaulCReichKGottliebAB. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014;28(12):1670-1675.
42.
AugustinMAbeysingheSMallyaU. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response—results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016;30(4):645-649.
43.
McInnesIBMeasePJKirkhamB. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137-1146.
44.
MeasePJMcInnesIBKirkhamB. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329-1339.
45.
LeonardiCMathesonRZachariaeC. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-1199.
46.
GordonKBLeonardiCLLebwohlM. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71(6):1176-1182.
47.
GriffiCEMReichKLebwohlM. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551.
48.
LangleyRGRichPMenterA. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2015;29(9):1763-1770.
49.
SaekiHNakagawaHIshiiT. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatology Venereol. 2015;29(6):1148-1155.
50.
BauerELucierJFurstDE. Brodalumab—an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis. Expert Opin Biol Ther. 2015;15(6):883-893.
51.
PappKALeonardiCMenterA. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-1189.
52.
PappKMenterAStroberB. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2015;72(3):436-439.
53.
PappKAReichKPaulC. A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. In press.
54.
LebwohlMStroberBMenterA. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-1328.
55.
PappKLeonardiCMenterA. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71(6):1183-1190.
56.
CuaDJTatoCM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10(7):479-489.
57.
GaffenSLJainRGargAVCuaDJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585-600.
58.
SchwarzenbergerPLa RussaVMillerA. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol. 1998;161(11):6383-6389.
59.
KryczekIBruceATGudjonssonJE. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008;181(7):4733-4741.
60.
BalzolaFCullenGHoGTRussellRKWehkampJ. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Inflamm Bowel Dis Monit. 2012;13(1):27-28.
61.
DaneshMJKimballAB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016;74(1):190-192.
